US regulatory status: approved. Molecular target: Fatty-acid amide hydrolase 1.
- Target
- Fatty-acid amide hydrolase 1
- Mechanism
- Cyclooxygenase inhibitor
biotech · Hypertriglyceridemia · Candidiasis, Chronic Mucocutaneous · MTNB
Matinas BioPharma Holdings
Matinas BioPharma Holdings drug portfolio — 5 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Bedminster, USA HQ
2011 Founded
16 Employees
Public company Type
MTNB · NYSE Ticker
Company details
- Status
- Public
- HQ
- Bedminster, USA
- Founded
- 2011
- Employees
- 16
- Programs
- 9
- Drugs
- 5
- Patents
- 8
Matinas BioPharma Holdings pipeline
Portfolio lens on 5 drugs and development assets — regulatory status, targets, and deep links to NovaPharmaNews drug profiles.
Matinas BioPharma Holdings drug portfolio — 5 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Drug portfolio
-
-
US regulatory status: approved. Molecular target: Ergosterol.
- Target
- Ergosterol
- Mechanism
- Ergosterol sequestering agent
-
US regulatory status: approved. Molecular target: Cyclooxygenase.
- Target
- Cyclooxygenase
- Mechanism
- Cyclooxygenase inhibitor
-
US regulatory status: approved. Mechanism: Supplement.
- Mechanism
- Supplement
-
Development asset linked to Matinas BioPharma Holdings in public FDA and regional records.